Balance Sheet
Accounts PayablesAccumulated DepreciationAccumulated ExpensesAssetsCash & EquivalentsCommon EquityCurrent AssetsCurrent LeasesGoodwillGoodwill & IntangiblesIntangiblesInventoryLiabilities and Shareholders EquityNon-Current AssetsNon-Current DebtOperating LeasesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)ReceivablesReceivables - NetRetained EarningsShareholder's EquityTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

CG Oncology (CGON) Preferred Stock Liabilities (2023)

Historic Preferred Stock Liabilities for CG Oncology (CGON) over the last 1 years, with Q4 2023 value amounting to $120.0 million.

  • CG Oncology's Preferred Stock Liabilities changed N/A to $120.0 million in Q4 2023 from the same period last year, while for Dec 2023 it was $120.0 million, marking a year-over-year change of. This contributed to the annual value of $120.0 million for FY2023, which is N/A changed from last year.
  • Per CG Oncology's latest filing, its Preferred Stock Liabilities stood at $120.0 million for Q4 2023.
  • Over the past 5 years, CG Oncology's Preferred Stock Liabilities peaked at $120.0 million during Q4 2023, and registered a low of $120.0 million during Q4 2023.